Wutah bathi EPS kuartalan Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA) relies on exclusive patents in psychopharmacology, allowing for flexible pricing power over orphan drugs. The quarter-over-quarter EPS dynamics provided by GURU.Markets demonstrate the current metric 2.40. Stable cash flow from mature products and adherence to ESG standards in bio-development create a solid foundation for the company's long-term growth.

Vanda Pharmaceuticals Inc. (VNDA) - Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan saka 04.07.2022 nganti 15.11.2026

Rincian metrik keuangan lan pasar Vanda Pharmaceuticals (VNDA)

- rega saham lan konsensus proyeksi valuasi:

Kutipan saham vandapharma.com|VNDA - Rata-rata rega prakiraan

- rincian kapitalisasi pasar:

Kapitalisasi pasar Vanda Pharmaceuticals Inc.|VNDA - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- indikator nilai aset resik miturut neraca:

Nilai Buku saben Saham Vanda Pharmaceuticals|VNDA - Nilai Akuntansi Perusahaan|Rasio Nilai Pasar marang Nilai Buku vandapharma.com|VNDA - Aset Perusahaan

- rincian utang lan likuiditas:

Rasio Total Utang marang Ekuitas Vanda Pharmaceuticals|VNDA - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal vandapharma.com|VNDA - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Vanda Pharma|VNDA - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Vanda Pharmaceuticals|Rasio cepet vandapharma.com

- indikator bathi lan kelipatan valuasi:

VNDA - Bathi resik|Bathi mangsa ngarep Vanda Pharmaceuticals|VNDA - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep Vanda Pharmaceuticals Inc|VNDA - Rasio kapitalisasi marang bathi lan wutah|Pangali EV/EBITDA Vanda Pharmaceuticals Inc.|VNDA - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Vanda Pharmaceuticals|VNDA - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan vandapharma.com|VNDA - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Vanda Pharmaceuticals

- indikator pendapatan dodolan lan penghasilan bisnis:

VNDA - Dodolan perusahaan|Prakiraan volume dodolan Vanda Pharma|VNDA - Multiplikator P/S|Multiplikator Forward P/S Vanda Pharmaceuticals Inc.

Analisis wiwitan perusahaan:Vanda Pharmaceuticals

Vanda Pharmaceuticals (VNDA) occupies the niche of a developer of targeted drugs for the therapy of CNS disorders, leveraging robust R&D potential. Earnings per share dynamics reflect the efficiency of monetizing these innovations and the company's ability to create shareholder value. By analyzing the intensity of quarterly EPS growth, investors assess the rate of net income increase relative to market expectations. A positive trend confirms financial stability and the potential for payouts. The stability of this metric testifies to the fundamental strength of the biopharmaceutical business.

Pesaing wigati